Search results for "MORBIDITY"

showing 10 items of 986 documents

Position paper on the management of patients with obstructive sleep apnea and hypertension: joint recommendations by the European Society of Hyperten…

2012

This article is aimed at addressing the current state of the art in epidemiology, pathophysiology, diagnostic procedures and treatment options for appropriate management of obstructive sleep apnea (OSA) in cardiovascular (particularly hypertensive) patients, as well as for the management of cardiovascular diseases (particularly arterial hypertension) in OSA patients. The present document is the result of the work done by a panel of experts participating in the European Union COST (COoperation in Scientific and Technological research) ACTION B26 on OSA, with the endorsement of the European Respiratory Society (ERS) and the European Society of Hypertension (ESH). These recommendations are par…

Societies Scientificmedicine.medical_specialtyPhysiologyArterial hypertension continuous positive airway pressure treatment guidelines hypertension treatment obstructive sleep apnoeaComorbiditySettore MED/10 - Malattie Dell'Apparato RespiratorioCheyne–Stokes respirationEpidemiologyarterial hypertension continuous positive airway pressure treatment guidelines hypertension treatment obstructive sleep apneaInternal MedicinemedicineHumansmedia_common.cataloged_instanceEuropean unionIntensive care medicinemedia_commonSleep Apnea Obstructivebusiness.industrySleep apneaMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareComorbidityEuropeSurvival RateObstructive sleep apneaBlood pressureHypertensionPractice Guidelines as TopicPosition papermedicine.symptomCardiology and Cardiovascular Medicinebusiness
researchProduct

Omalizumab and COVID-19 treatment: Could it help?

2020

Special Issue ArticlesCoronavirus disease 2019 (COVID-19)UrticariaPneumonia ViralMEDLINEOmalizumabDermatologyComorbidityOmalizumabBetacoronavirusCOVID‐19PandemicAnti-Allergic AgentsmedicineHumansPandemicsbiologybusiness.industryViral EpidemiologySARS-CoV-2COVID-19Special Issue ArticleGeneral Medicinemedicine.diseasebiology.organism_classificationVirologyComorbidityPneumoniaTherapybusinessCoronavirus InfectionsBetacoronavirusmedicine.drugDermatologic therapy
researchProduct

Psoriatic arthritis and COVID ‐19 pandemic: Consequences in medical treatment?

2020

The COVID‐19 pandemic has a strong negative impact on human society world‐wide. Patients with immune‐mediated disease may be prone to an increased risk of infection and/ or more severe course. We review the available data for patients with psoriatic arthritis (PSA) and systemic treatments. Current treatment options are summarized. Based upon the experience with COVID‐19 the following problems are addressed: (a) Can systemic treatment reduce comorbidities of PsA that are also comorbidities for COVID‐19? Does systemic medical treatment pose an increased risk of infection with SARS‐CoV‐2? Does systemic drug therapy have an impact on the risk of pulmonary fibrosis ‐ a factor with strong negativ…

Special Issue Articlesmedicine.medical_specialtyDiseaseComorbidityDermatologyPlacebo030207 dermatology & venereal diseases03 medical and health sciencesPsoriatic arthritisPsoriatic arthritis; systemic medical treatment0302 clinical medicinePharmacotherapyCOVID‐19Internal medicinePandemicmedicineHumansJanus Kinase InhibitorsbiologicsBiological Productsbusiness.industrySARS-CoV-2Tumor Necrosis Factor-alphaArthritis PsoriaticInterleukinSpecial Issue ArticleCOVID-19General Medicinemedicine.diseaseComorbiditysmall molecules030220 oncology & carcinogenesisAirwaybusinessDermatologic Therapy
researchProduct

The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline

2016

Abstract Background The German COPD cohort study COSYCONET (" CO PD and SY stemic consequences- CO morbidities NET work") investigates the interaction of lung disease, comorbidities and systemic inflammation. Recruitment took place from 2010 to 2013 in 31 study centers. In addition to the baseline visit, follow-up visits are scheduled at 6, 18, 36 and 54 months after baseline. The study also comprises a biobank, image bank, and includes health economic data. Here we describe the study design of COSYCONET and present baseline data of our COPD cohort. Methods Inclusion criteria were broad in order to cover a wide range of patterns of the disease. In each visit, patients undergo a large panel …

SpirometryAdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyComorbiditySeverity of Illness IndexCohort Studies03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineRisk FactorsInternal medicineGermanySeverity of illnessMedicineHumansCOPD030212 general & internal medicineProspective StudiesProspective cohort studyAgedAged 80 and overCOPDmedicine.diagnostic_testSystemic inflammationbusiness.industrySmokingCohortStudy designMiddle Agedmedicine.diseaseComorbiditySystemic Inflammatory Response SyndromeObservational Studies as Topic030228 respiratory systemCohortPhysical therapyDisease ProgressionPopulation studyFemaleCohort ; Comorbidity ; Copd ; Study Design ; Systemic InflammationbusinessCohort studyFollow-Up StudiesRespiratory Medicine
researchProduct

Comorbidities and quality of life in obstructed adults in a primary care setting

2016

Introduction: Comorbidities are known to impair Quality of Life (QoL)in patients with chronic obstruction pulmonary disease. A poor QoL is associated with higher dyspnoea perception. How comorbidities influence QoL in these patients is limited and needs clarification. Aim: To study the role of dyspnoea perception in the relationship between comorbidities number and QoL in obstructed and not obstructed adults in a primary care setting. Methods: Seventeen general practitioners participated to the study: 566 adults, attending the Practitioner9s study for any reason, performed spirometry and fulfilled a respiratory questionnaire between January and June 2014. 259 adults (148 M, aged 40-88) acce…

Spirometrymedicine.medical_specialtyQuality of life. Spirometry Comorbiditiesmedicine.diagnostic_testbusiness.industrySignificant differencePrimary caremedicine.diseaseComorbidityMental healthhumanitiesFEV1/FVC ratioQuality of lifemedicineGlobal healthPhysical therapybusiness
researchProduct

Analysis of hospital costs by morbidity group for patients with severe mental illness

2022

The goal of this study is to analyse hospital costs and length of stay of patients admitted to psychiatric units in hospitals in a European region of the Mediterranean Arc. The aim is to identify the effects of comorbidities and other variables in order to create an explanatory cost model.In order to carry out the study, the Ministry of Health was asked to provide data on access to the mental health facilities of all hospitals in the region. Among other questions, this database identifies the most important diagnostic variables related to admission, like comorbidities, age and gender. The method used, based on the Manning-Mullahy algorithm, was linear regression. The results were measured b…

Substance-Related DisordersMental DisordersHospitals AdministracióHumansGeneral MedicineHospital CostsLength of StayMorbiditySalut mentalHospitals
researchProduct

Use of Different Food Classification Systems to Assess the Association between Ultra-Processed Food Consumption and Cardiometabolic Health in an Elde…

2021

The PREDIMED-Plus trial was supported by the European Research Council (Advanced Research grant 2014–2019; agreement #340918; granted to M.Á.M.-G.); the official Spanish institutions for funding scientific biomedical research, CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN) and Instituto de Salud Carlos III (ISCIII) through the Fondo de Investigación para la Salud (FIS) which is co-funded by the European Regional Development Fund (coordinated FIS projects led by J.S-S. and J.V., including the following projects: PI13/00673, PI13/00492, PI13/00272, PI13/01123, PI13/00462, PI13/00233, PI13/02184, PI13/00728, PI13/01090, PI13/01056, PI14/01722, PI14/00636, PI14/00618, PI14/00696, PI…

Síndrome metabólicoMaleFood processingMediterranean dietNOVAObesidadÍndice de masa corporal:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]0302 clinical medicineultra-processed foodMedicineTX341-641:Diseases::Pathological Conditions Signs and Symptoms::Signs and Symptoms::Body Weight::Overweight [Medical Subject Headings]Body mass indexclassification systemsIncidenceIARC:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Questionnaires [Medical Subject Headings]Metabolic syndrome3. Good healthNutriciónCohortManipulación de alimentosDietaFactores de riesgo cardiometabólicoConcordanceUNC:Check Tags::Male [Medical Subject Headings]ClasificaciónClassification systemsDiet SurveysArticle03 medical and health sciencesfood processingHumans:Diseases::Cardiovascular Diseases [Medical Subject Headings]Aged030109 nutrition & dietetics:Health Care::Health Care Economics and Organizations::Organizations::International Agencies [Medical Subject Headings]:Persons::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings]PREDIMED-Plusmedicine.diseaseObesity:Diseases::Nutritional and Metabolic Diseases::Nutrition Disorders::Overnutrition::Obesity [Medical Subject Headings]Blood pressure:Check Tags::Female [Medical Subject Headings]:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies [Medical Subject Headings]Linear ModelsFast FoodsMetabolic syndromeOlder people0301 basic medicineSíndrome metabòlicaFood HandlingOverweightDiet MediterraneanPersones gransCohort Studiescardiometabolic riskEndocrinología030212 general & internal medicine:Persons::Persons::Age Groups::Adult::Aged [Medical Subject Headings]2. Zero hungerMetabolic SyndromeNutrition and Dietetics:Technology and Food and Beverages::Technology Industry and Agriculture::Industry::Food Industry::Food Handling [Medical Subject Headings]:Analytical Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Nutrition Therapy::Diet Therapy::Diet Mediterranean [Medical Subject Headings]Middle Aged:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Health Surveys::Nutrition Surveys::Diet Surveys [Medical Subject Headings]Female:Technology and Food and Beverages::Food and Beverages::Food::Fast Foods [Medical Subject Headings]medicine.symptom:Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Hyperinsulinism::Insulin Resistance::Metabolic Syndrome X [Medical Subject Headings]Dietética y nutrición:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Physical Examination::Body Constitution::Body Weights and Measures::Body Mass Index [Medical Subject Headings]:Phenomena and Processes::Physiological Phenomena::Nutritional Physiological Phenomena::Diet [Medical Subject Headings]:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Incidence [Medical Subject Headings]Environmental healthMediterranean dietObesityAlimentos ultraprocesados:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Models Statistical::Linear Models [Medical Subject Headings]NutricióNutrition:Geographical Locations::Geographic Locations::Europe::Spain [Medical Subject Headings]business.industryNutrition. Foods and food supplyCardiometabolic Risk FactorsOverweightDieta mediterráneaCardiometabolic riskUltra-processed foodDietSpainIFICSobrepesoFood processingbusinessdietFood ScienceNutrients
researchProduct

Familial amyloidosis: great progress for an orphan disease.

2015

Familial amyloidosis: Great progress for an orphan disease Ana Paula Barreiros1,2,*, Gerd Otto3, Bita Kahlen1, Andreas Teufel1,2, Peter R. Galle1 1Department of Internal Medicine I, Universitatsmedizin of the Johannes Gutenberg-University Mainz, Germany; 2Department of Internal Medicine I, Universitatsklinikum of the University Regensburg, Germany; 3Department of Hepatobiliary and Transplantation Surgery, Universitatmedizin of the Johannes Gutenberg-University Mainz, Germany. *Corresponding author. Address: Universitatsklinikum Regensburg, Department of Internal Medicine I, Franz-Josef-Strauss Allee 11, 93053 Regensburg, Germany. Tel.: +49 941-944-7021. E-mail address: Ana.Barreiros@ukr.de …

TafamidisFamilial amyloidosismedicine.medical_specialtyPathologyPharmacological therapymedicine.medical_treatmentDiseaseLiver transplantationGlobal Healthchemistry.chemical_compoundRare DiseasesMedicineHumansTransplantation surgeryLiver transplantationHepatologybusiness.industryGeneral surgerymusculoskeletal neural and ocular physiologyDisease ManagementPharmacological therapymedicine.diseaseTafamidissurgical procedures operativechemistryGERDMorbiditybusinessFamilial amyloidosisAmyloidosis FamilialJournal of hepatology
researchProduct

Age, morbidity, or something else? A residual approach using microdata to measure the impact of technological progress on health care expenditure

2020

This study measures the increment of health care expenditure (HCE) that can be attributed to technological progress and change in medical practice by using a residual approach and microdata. We examine repeated cross-sections of individuals experiencing an initial health shock at different point in time over a 10-year window and capture the impact of unobservable technology and medical practice to which they are exposed after allowing for differences in health and socioeconomic characteristics. We decompose the residual increment in the part that is due to the effect of delaying time to death, that is, individuals surviving longer after a health shock and thus contributing longer to the dem…

TechnologyCross-Sectional StudiesSocioeconomic FactorsHealth PolicytechnologicalDenmarkagingAge FactorsHumanshealth care expendituremorbiditytime-to-deathHealth Expenditures
researchProduct

2016

Abstract Background: The association of attention-deficit/hyperactivity disorder (ADHD) and tic disorder (TD) is frequent and clinically important. Very few and inconclusive attempts have been made to clarify if and how the combination of ADHD+TD runs in families. Aim: To determine the first time in a large-scale ADHD sample whether ADHD+TD increases the risk of ADHD+TD in siblings and, also the first time, if this is independent of their psychopathological vulnerability in general. Methods: The study is based on the International Multicenter ADHD Genetics (IMAGE) study. The present sub-sample of 2815 individuals included ADHD-index patients with co-existing TD (ADHD+TD, n=262) and without …

Tic disordermedicine.medical_specialty05 social sciencesmedicine.diseasebehavioral disciplines and activitiesComorbidityTourette syndrome3. Good health03 medical and health sciences0302 clinical medicineRating scalemental disordersmedicineCriterion validityAttention deficit hyperactivity disorder0501 psychology and cognitive sciencesSiblingPsychologyPsychiatry030217 neurology & neurosurgeryGeneral Psychology050104 developmental & child psychologyClinical psychologyPsychopathologyFrontiers in Psychology
researchProduct